[2]
Alzforum. A year of hope for Alzheimer’s Research. https://www.alzforum.org/news/research-news/2019-year-hope-alzheimers-research (Feb 10, 2020.).
[3]
Alzforum. Topline result for first DIAN-TU clinical trial: Negative
on primary. https://www.alzforum.org/news/research-news/topline-result-first-dian-tu-clinical-trial-negative-primary (Feb 10, 2020.).
[4]
Zhao Y, Tudorascu DL, Lopez OL, Cohen AD, Mathis CA, Aizenstein HJ, et al. Amyloid beta deposition and suspected non-Alzheimer pathophysiology and cognitive decline patterns for 12 years in oldest old participants without dementia. JAMA Neurol 75(1): 88-96. (2018).
[5]
Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun 11(1): 667. (2020).
[6]
Li JG, Chiu J, Ramanjulu M, Blass BE, Pratico D. A pharmacological chaperone improves memory by reducing Abeta and tau neuropathology in a mouse model with plaques and tangles. Mol Neurodegener 15(1): 1. (2020).
[7]
Yan R, Munzner JB, Shuck ME, Bienkowski MJ. BACE2 functions as an alternative alpha-secretase in cells. J Biol Chem 276(36): 34019-27. (2001).
[8]
Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci USA 97(17): 9712-7. (2000).
[9]
Sun X, He G, Song W. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer’s disease in Down syndrome. FASEB J 20(9): 1369-76. (2006).
[10]
Jung ME. A protective role of translocator protein in Alzheimer’s disease brain. Curr Alzheimer Res 17(1): 3-15. (2020).
[11]
Brzezińska A, Bourke J, Rivera-Hernández R, Tsolaki M, Woźniak J, Kaźmierski K, et al. Depression in dementia or dementia in depression? systematic review of studies and hypotheses. Curr Alzheimer Res 17(1): 16-28. (2020).
[12]
Süß P, Schlachetzki JCM. Microglia in Alzheimer’s disease. Curr Alzheimer Res 17(1): 29-43. (2020).
[13]
Wang Y, Lv W, Li Y, Liu D, He X, Liu T. Ampelopsin improves cognitive impairment in Alzheimer’s disease and effects of inflammatory cytokines and oxidative stress in the hippocampus. Curr Alzheimer Res 17(1): 44-51. (2020).
[14]
Ano Y, Ikado K, Uchida K, Nakayama H. Amyloid β-induced mesenteric inflammation in an alzheimer’s disease transgenic mouse model. Curr Alzheimer Res 17(1): 52-9. (2020).
[15]
Nagumo R, Zhang Y, Ogawa Y, Hosokawa M, Abe K. Automatic detection of cognitive impairments through acoustic analysis of speech. Curr Alzheimer Res 17(1): 60-8. (2020).
[16]
Gao Z, Feng Y, Ma C, Ma K, Cai Q. and for the Alzheimer’s Disease Neuroimaging Initiative. Disrupted time-dependent and functional connectivity brain network in alzheimer’s disease: a resting-state fmri study based on visibility graph. Curr Alzheimer Res 17(1): 69-79. (2020).
[17]
Gadomsky L, dos Santos Guilherme M, Winkler J, van der Kooij M, Hartmann T, Grimm M, et al. Elevated testosterone level and urine scent marking in male 5xFAD Alzheimer model mice. Curr Alzheimer Res 17(1): 80-92. (2020).
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research-Dementia
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Article Metrics
8
1